The Manila Times

Roche’s fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)

Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the current standard of care, OCREVUS, in ...
Le Lézard

Genentech's Fenebrutinib Is the First Investigational Medicine in Over a Decade That Reduces Disability Progression in Primary Progressive Multiple Sclerosis (PPMS)

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new late-breaking data from the Phase III FENtrepid study showing the investigational Bruton's tyrosine kinase (BTK ...

F. Hoffmann-La Roche Ltd: Roche's fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple ...

Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the current standard of care, OCREVUS, in reduc ...
VRM Intel

Play Confidently Win Bravely at DuxCasino in United Kingdom

DuxCasino in the UK promotes a unique motto: "Play Confidently, Win Bravely." This philosophy is reflected in its diverse game offerings, which encompass ...
Tax Guru

Controlled Cant Benchmark Controlled – Pro-Rata Commission TP Struck Down

The authorities compared intra-group commission rates without economic analysis. The Tribunal ruled that such an approach leads to invalid transfer pricing ...